Lenstec, Inc. is a Florida-based medical device corporation serving the global ophthalmic surgical market, with products currently marketed in more than 60 countries. We design, manufacture and distribute a wide range of intraocular lens (IOL) implants and lens injection systems, and have an established reputation for rapid prototype design and development and high quality/low cost manufacturing.
The ClearView™ is a next generation multifocal lens which provides patients with near, intermediate, and a distance vision.
Learn more
ClearView 3 is a rotationally asymmetric MIOL designed to improve contrast sensitivity, minimize dysphotopsias like halos and glare, and provide superior near, intermediate, and far vision compared to other presbyopic IOLs.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.
Lenstec Inc has announced that it has rebranded its new multifocal IOL, the SBL-3, to the ClearView 3.
Lenstec, Inc. (St. Petersburg, FL) is proud to announce today, that the first U.S. commercial implantations of their newly FDA approved ClearView Multifocal Intraocular lens (MIOL) were performed by Jeff Whitsett, MD of Whitsett Vision (Houston, TX).
Lenstec Inc has announced that it has rebranded its new multifocal IOL, the SBL-3, to the ClearView 3.
“ClearView provides high quality distance, intermediate and near vision and due to the ClearView optic being designed without concentric rings, I believe my patients have limited glare and halos at night compared to other multifocal lenses on the market. My FDA study patients still have excellent vision and are free from glasses. I see them every year and it makes me confident to recommend the ClearView to my patients today.”
“My initial thought was, this is a very straight lens to implant and very forgiving with excellent patient satisfaction.”
“Patients have reported high levels of satisfaction with minimal side effects. I believe the SBL-3 will be an excellent option for refractive lens surgeons to offer their patients seeking their best vistion and independence from glasses after cataract surgery. No patients in the study reported negative dysphotopsia and reported a 94% rate of spectacle independence.”
